Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to improve COPD care by checking the heart too

NCT ID NCT07481825

Disease control Sponsor: University of Bari Aldo Moro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a thorough heart evaluation to standard lung care helps people with mild-to-moderate COPD who also have heart risks. About 350 adults will be randomly assigned to either the combined heart-lung check or usual respiratory care. The goal is to see if the combined approach improves heart function, exercise ability, and quality of life over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
structured combined cardio-pulmonary clinical management strategy
What this could lead to
If it works, this could lead to a better way to manage COPD patients who also have heart problems, potentially improving their heart function and daily life.
What could go wrong
This is an early-stage study with no results yet. The added heart tests may not lead to better outcomes, and the findings may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

41 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients enrolled in the study should be diagnosed as COPD according to international recommendations (1) with the following features: * Post-bronchodilator FEV1 ≥ 50% or FEV1 z ≥ -2.5 * Age \> 40 years Additionally, enrolled patients must fulfill at least one of the following cardiovascular criteria: * Very high cardiovascular risk * according to SCORE2 (12)for patient \< 70 years old and defined as follows: * Patients \< 50 years old \> 7.5% * Patients 50-69 years old \> 10% * according to SCORE OP 2 (13) calculator for patients \> 70 years old and defined as \> 15% * History of ischemic heart disease * Chronic or transient atrial fibrillation * Chronic heart failure with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction (EF \> 40%) (14) Exclusion Criteria: * Post-bronchodilator FEV1 \< 50% or FEV1 z \< -2.5 * LTOLT * Active neoplasm * Patient unable to perform lung function * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease COPD (chronic obstructive pulmonary disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.